Kornimate/medical-research-clean huggingface dataset:
acute lymphoblastic leukemia registry at asan medical center

Conditions: Leukemia, Acute Lymphoblastic; Precursor B-Cell Lymphoblastic Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Lymphoblastic Lymphoma

Summary: the investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at asan medical center, seoul, korea, to use the acquired data for fundamentals of other retrospective analysis.

1. acquisition of informed concent form 2. data acquisition from medical record including * demographic / disease-associated factors * details of treatment, and its results * complications during treatment * genetic data * survival outcome (upto 10 years) 3. accumulation of data for 30 years 4. use of data for other retrospective analysis (including asan medical center cell banking basic data)

Eligibility criteria:
inclusion criteria: * all patients who are diagnosed and/or treated as acute lymphoblastic leukemia at asan medical center (including biphenotypic acute leukemia with philadelphila-positive, burkitt leukemia/lymphoma) * 15 years of age and over * all patients who give written consent according to guidelines at asan medical center committee on human research exclusion criteria: * patients who refuse to give consent to registering
brain imaging studies of the effects of cocaine abstinence

Conditions: Substance Abuse Disorder

Summary: this study evaluates theories regarding cocaine abstinence which propose that increased presynaptic and postsynaptic dopamine activity and increased serotonin activity are associated with abstinence in cocaine dependent subjects at the beginning and three to six months after a treatment program. we are using positron emission tomography (pet), magnetic resonance imaging (mri) and diffusion tensor imaging (dti) in cortical and subcortical areas in a series of brain imaging studies testing these theories of abnormalities in the dopamine and serotonin system for cocaine addiction by examining the distribution of 18f-fallypride, 18f-altanserin, and fdg. we are evaluating genetic theories associated with cocaine addiction through the examination of genetic markers and functional genomics.


Eligibility criteria:
inclusion criteria: inclusion criteria include: 1. subjects must be male or female and english speaking. 2. subjects must be adults with a history of diagnosis of cocaine dependence disorder (n=20) who are under supervised treatment for dependence or normal control (n=10). 3. subjects must be between 21 to 65 years of age. exclusion criteria: exclusion criteria include: 1. suicidality or psychosis. 2. head injury, kidney or bladder disease or any unstable or serious medical conditions. 3. prior exposure to radiation (including diagnostic or treatment x-rays), which might cause subjects to exceed standard guidelines. 4. unwillingness or inability to adhere to the requirements of the study. 5. donation or large loss of blood (\>400 ml) within the past month. 6. current or very recent illnesses, painful conditions or other disorders, which in the judgment of the investigators, might invalidate the scientific goals of the study or pose undesirable difficulties or risks for subjects. 7. pregnancy or breast feeding. 8. individuals who would be unable to undergo a magnetic resonance imaging (mri) scan, for example, individuals who suffer from claustrophobia, or who have metal clips in their body, metallic prostheses (i.e., replacement body parts, such as a hip joint), a pacemaker, or other pieces of metal in their body (shrapnel, metal filings, etc.).

Keywords: cocaine abstinence pet scan
efficacy and safety study of a recombinant and protein-free factor viii (rahf-pfm) in pediatric patients in canada with hemophilia a - a continuation of baxter study 060101

Conditions: Hemophilia A

Summary: the purpose of this study is to evaluate whether rahf-pfm is safe and effective in the treatment of children with hemophilia a. the study is open to pediatric patients in canada who completed baxter study 060101.


Eligibility criteria:
inclusion criteria: * subject must have participated and completed participation in baxter's clinical study 060101 * subject or parent/legally authorized representative has provided written informed consent exclusion criteria: * subjects who have withdrawn from baxter's clinical study 060101 prior to the termination of the study

Keywords: factor viii deficiency
does extraction difficulty of mandibular impacted third molars mirror post-op outcomes?

Conditions: Impacted Third Molar Tooth

Summary: the tooth of the patient who applies to the clinic for the impacted wisdom tooth will be classified according to escoda's difficulty classification. before the extraction, patients' interincisal, tragus-commissural, and lateral canthus-angulus distances, oral health impact profile -14 (ohip-14) scores, and serum levels of crp and d-dimer will be measured. operation time will be recorded. after the operation, on 4th-day patients' patients' interincisal, tragus-commissural, and lateral canthus-angulus distances, oral health impact profile -14 (ohip-14) scores, and serum levels of crp and d-dimer and visual analogue scale (for pain) scores will be measured and recorded. on the 10th day, all these measurements will be repeated. all recorded data will be evaluated for possible correlations based on extraction difficulties.


Eligibility criteria:
inclusion criteria: * having extraction of only the mandibular third molar * no systemic disease * signing an informed consent * no dental phobia or anxiety * no lesion around the impacted tooth * presence of adjacent second molar exclusion criteria: * infection after surgery * alveolar osteitis * not to participate in any follow-up control appointments
the study to evaluate efficacy and safety of newrabell® tab.(rabeprazole sodium) 10mg b.i.d in refractory gerd

Conditions: Reflux Esophagitis

Summary: the purpose of this study is to assess the efficacy and safety of newrabell® tab. in patients with refractory reflux esophagitis to the prior standard ppis regimen.


Eligibility criteria:
inclusion criteria: 1. male or female aged ≥ 20 years 2. reflux esophagitis with erosion or ulceration confirmed by endoscopic exam. 3. refractory reflux esophagitis to ppis standard treatment as follows 1. ongoing heartburn symptom with or without these gerd-related symptoms : regurgitation, non-cardiac chest pain, epigastric pain, belching, bloating, satiety, sore throat, cough, laryngitis, hoarseness, nausea, vomiting, dysphagia, odynophagia, weight loss 2. ongoing heartburn symptom with or without erosion ≥ grade a according to la classification 4. ongoing heartburn symptoms ≥ 2 days during 1week right before administering first dose of ip 5. decided to participate and signed on an informed consent form willingly exclusion criteria: 1. existence of upper gastrointestinal bleeding or active gastroduodenal ulcer at screening 2. history of operation in esophagus, stomach or duodenum 3. the following medical history 1. primary esophageal motility disease, achalasia, scleroderma, esophageal/pyloric stricture, primary esophageal spasm 2. barrett's esophagus ≥ 3 cm 3. zollinger-ellison syndrome 4. infectious or inflammatory bowel disease, severe malabsorption 4. severe chronic heart failure, cardiovascular disease, renal failure, copd, asthma, liver cirrhosis 5. history of cancer within 5 years, except completely recovered skin cancer 6. alt or ast ≥ upper limit of normal range x 3 7. need antibiotics due to severe infection 8. severe medical disease that needs these prohibited medication * anticoagulant(heparin, warfarin, etc.), high dose of aspirin(\>325mg/d), digitalis(digoxin, etc.), diuretics, atazanavir, nsaids or steroids 9. use ppis or h2ra medicine within 1 week before administering first dose of ip, or need other ppis or h2ra medicine during trial period 10. allergy or hypersensitivity to ip or similar chemical structure(benzimidazol derivatives, etc.) 11. pregnant or breast-feeding women 12. conversation impairment because of alcohol, drug addiction or mental illness, etc. 13. administration of other ip within 28 days 14. inability to record heartburn diary card 15. in investigator's judgement

Keywords: refractory reflux esophagitis gerd phase 4
pilot study of the chills cryotherapy system for the treatment of osa

Conditions: Obstructive Sleep Apnea of Adult

Summary: this is a prospective, multicenter, non-randomized single-arm safety and efficacy study to: * collect data to evaluate the safety of chills cryotherapy to treat osa in patients with moderate to severe disease. * evaluate the chronic performance of the chills system and collect clinical measures for therapy effectiveness that will be used to demonstrate safety and effectiveness in the next clinical study.

the study will enroll up to 3 sites in latin america, enrollment is competitive. up to 70 subjects will receive treatment and be followed through their 3-month visit. long-term follow-up will continue every 6 months out to 2 years post-procedure, with an option to follow patients up to 5 years.

Eligibility criteria:
inclusion criteria: likely suffer moderate to severe osa based on history and physical or have an established diagnosis of moderate to severe osa (ahi ≥ 10) based on a prior sleep study. a confirmation baseline sleep study will be performed after enrollment to verify ahi ≥ 10 and ≤ 50, and mixed and central apneas total ≤ 25% of apneas for continued eligibility. have either failed positive airway pressure (pap) therapy or decline pap therapy bmi of 25 - 40 kg/m2 at enrollment negative result for covid-19 polymerase chain reaction (rt-pcr) test and absence of clinical symptoms for long covid-19 relating to deterioration of taste, smell. exclusion criteria: unable or incapable of providing informed written consent unwilling or incapable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
evaluating occupational stress in surgeons and musicians: a multi-modal pilot study using wearable eeg, biomarker analysis and validated questionnaires

Conditions: Occupational Stress

Summary: to learn about occupational stress among surgeons and musicians by integrating psychological assessments, neurophysiological measures, and biomarkers.

primary objectives • to assess the change in occupational stress among surgeons and musicians by measuring physiological and psychological stress markers. endpoints: * changes in salivary cortisol levels (before and after surgeries for surgeons and live public performances for musicians). * changes in state-trait anxiety inventory-short (stai-s) scores (administered pre- and post-surgery/performance). secondary objectives and endpoints • assessing and comparing anxiety and burnout, based on the mbi, stai-t, m-pas, and scat, in surgeons and musicians endpoints: * baseline levels of anxiety and burnout measured using the mbi, m-pas, stai-t, and scat. * emotional exhaustion, depersonalization, and personal accomplishment from the mbi in both groups.

Eligibility criteria:
inclusion criteria: * adults aged 18 years and older * professional musicians (i.e., those with academic or orchestral appointments) or md anderson neurosurgeons * for musicians only: you will have a musical performance within three months of study enrollment. for neurosurgeons only: you will perform a surgical procedure within three months of study enrollment. exclusion criteria: * individuals who are unable to provide informed consent * individuals diagnosed with severe cognitive impairments, severe psychiatric disorders, or hearing or visual impairments that could affect participation * individuals previously enrolled in the study * non-english-speaking musicians and/or surgeons
repetitive transcranial magnetic stimulation in symptoms of attention deficit hyperactivity disorder and cognitive function in cocaine addicts

Conditions: Cognition Disorders; Cocaine Dependence; ADHD

Summary: even in the absence of a preliminary diagnosis of attention deficit hyperactivity disorder, symptoms of attention deficit, hyperactivity and cognitive impairment are common in cocaine addicts. several factors indicate that repetitive transcranial magnetic stimulation might be a strategy to aid in the treatment of symptoms of attention deficit hyperactivity disorder and cognitive function in cocaine addicts. however, up to current days there have been no studies evaluating the effects of repetitive transcranial magnetic stimulation (rtms) on neurocognitive performance of individuals suffering from the adhd.

transcranial magnetic stimulation is a noninvasive technique that can influence specific areas of the brain and has very few side effects. the treatment with transcranial magnetic stimulation requires attendance to hospital daily sessions for 4 consecutive weeks. each session lasts up to 30 minutes. side effects include scalp discomfort and mild headache. no anesthesia is required. stimulation aims the dorsolateral prefrontal cortex, a region previously studied to treat depression symptoms with positive results. the present technique has never been employed in previous studies, but risks are insignificant.

Eligibility criteria:
inclusion criteria: * cocaine dependence syndrome (alone or in combination with alcohol and/or nicotine dependence with symptoms of adhd, according to the criteria of the dsm-iv-r (apa, 2000), as well as through a structured clinical interview (scid-1/p v 2.0) * minimum age of 18 * maximum age of 40 * 20 days or less abstinence. * any psychopharmacological treatment other than clonazepam (4 mg/day) exclusion criteria: * metallic cerebral implant * pacemakers * history of severe brain trauma or injury * organic brain disease * previous neurosurgery * history of seizures * epilepsy * severe somatic disease * history of other actual or past psychiatric diagnostics * clinically significant changes in laboratory test * any psychiatric or neurological disorder other than cocaine dependence with symptoms of adhd * psychotic depression * suicidal propensities

Keywords: repetitive transcranial magnetic stimulation cocaine dependence cocaine addicts attention deficit hyperactivity disorder cognitive function
atherectomy followed by a drug coated balloon to treat peripheral arterial disease

Conditions: Peripheral Arterial Disease; Claudication

Summary: the definitive ar study is a prospective, multi-center, randomized pilot study evaluating the use of either the turbohawk™ or silverhawk® plaque excision systems followed by treatment with the cotavance™ drug-eluting balloon catheter versus the cotavance balloon catheter alone in patients with peripheral arterial disease.


Eligibility criteria:
inclusion criteria: * rutherford clinical category 2-4 * at least 18 years of age * is able and willing to provide written informed consent prior to study specific procedures exclusion criteria: * has a life expectancy of less than 24 months * is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing * has one or more of the contraindications listed in the silverhawk/ turbohawk or cotavance ifus

Keywords: peripheral arterial disease, claudication, atherectomy, plaque excision, drug-coated balloon drug-eluting balloon
mu opioid receptor 1 expression and activation patterns in colorectal cancer

Conditions: Colorectal Surgery for Stage II / III Primary Colorectal Cancer

Summary: observational case-control study in a retrospective cohort of patients with stage ii or iii colorectal cancer undergoing scheduled surgery.

observational case-control study in a retrospective cohort of patients with stage ii or iii colorectal cancer undergoing scheduled surgery. period january 2010-december 2014. patients must have had at least 5 years of follow-up to define disease-free survival. from the cohort of patients previously studied in our center by immunohistochemistry, 31 we will select 10 cases with recurrence by random sampling and we will match 10 controls by leveling the propensity score (propensity score matching).

Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * colorectal surgery scheduled between january 2010 - december 2014. * stage ii or iii colon or rectum neoplasm (t3 / t4 n + m0). exclusion criteria: * neoplasia of colon or rectum in stage i or stage iv. * non-oncological colorectal surgery. * urgent surgery
early body temperature targets and relationship with prognosis in patients with heat stroke

Conditions: Heat Stroke

Summary: the goal of this observational study is to explore the optimal target body temperature in first 24 hours and the relationship between body temperature and adverse outcomes of heat stroke. the main questions it aims to answer are: * the optimal target body temperature at 0.5 h, 2 h, and the lowest body temperature of heat stroke. * the best body temperature at the cutting point of stop cooling. * the relationship between the volume and speed of ice saline infusion and the cooling effect.


Eligibility criteria:
inclusion criteria: * ≥ 18 years; ② diagnosed as heat stroke; ③ informed consent from patients or family members. exclusion criteria: * need immediate cardiopulmonary resuscitation; ② transferred from another hospital; ③ with severe underlying organ insufficiency; ④ pregnant women.

Keywords: heat stroke, body temperature, outcomes
pcd versus rcd for the treatment of patients with waldenstrom's macroglobulinemia

Conditions: Treatment

Summary: patients will receive rcd or pcd combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try to compare the, very good partial remission (vgpr) rate, complete remission (cr) rates, overall remission rate (mr+cr + vgpr + partial remission (pr) rate), major reaction rate (mrr, pr+vgpr+cr) at the end of the research.

this is an open-label, single-centre, randomised study, looking at a series of 40 patients up to the age of 75 with newly diagnosed waldenstrom's macroglobulinemia (wm) not previously treated. patients will receive rcd or pcd combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try to compare the, very good partial remission (vgpr) rate, complete remission (cr) rates, overall remission rate (mr+cr + vgpr + partial remission (pr) rate), major reaction rate (mrr, pr+vgpr+cr) at the end of the research.

Eligibility criteria:
inclusion criteria: * recently diagnosed wm according to the second 2002 wm international working group * not previously treated, apart from not regularly received by chlorambucil * aged from 18 to 75 years, both male and female * ability to give signed informed consent * negative pregnancy test at inclusion (if necessary) * ecog from 0 to 2 exclusion criteria: * known hypersensitivity to rituximab or velcade or cyclophosphamide * uncontrolled infection including bacteria, virus and fungus, including active hbv infection * organic dysfunction: bilirubin \> 1.5 x normal above, renal failure requiring dialysis, glutamic pyruvic transaminase (alt) and glutamic-oxaloacetic aminotransferase (ast) \> 2.5 x normal above * positive hiv serology * serious psychiatric item in the history
gene therapy for metachromatic leukodystrophy (mld)

Conditions: Lysosomal Storage Disease; Metachromatic Leukodystrophy

Summary: this phase i/ii clinical trial consists of the application of lentiviral vector-based gene therapy to patients affected by metachromatic leukodystrophy (mld), a rare inherited lysosomal storage disorder (lsd) resulting from mutations in the gene encoding the arylsulfatase a (arsa) enzyme. the medicinal product consists of autologous cd34+ hematopoietic stem/progenitor cells in which a functional arsa cdna is introduced by means of 3rd generation vsv-g pseudotyped lentiviral vectors.


Eligibility criteria:
inclusion criteria: * pre-symptomatic mld patients with the late infantile variant; * pre- or early-symptomatic mld patients with the early juvenile variant; * patients for whom parental/guardian signed informed consent has been obtained. exclusion criteria: * hiv rna and/or hcv rna and/or hbv dna positive patients; * patients affected by neoplastic diseases; * patients with cytogenetic alterations typical of mds/aml; * patients with end-organ functions or any other severe disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study; * patients enrolled in other trials/other therapeutic approaches that might become available; * patient who underwent allogeneic hematopoietic stem cell transplantation in the previous six months; * patient who underwent allogenic hematopoietic stem cell transplantation with evidence of residual cells of donor origin.

Keywords: otl-200 metachromatic leukodystrophy gene therapy mld previously gsk2696274
gene x environment interplay in developmental dyslexia treatment: a round-trip translation between humans and animal

Conditions: Reading Disorder

Summary: developmental dyslexia affects 7% of school-age children (male:female ratio of 1.5:1) and incurs disadvantages in education and occupation. scientific progress concerning the etiology of developmental dyslexia evidenced the complex gene-environment interaction. the dcdc2-read1 deletion associates with reading skills and affects the magnocellular-dorsal stream in humans and animals. dcdc2 modifies neural activity within the excitatory pathways. the magnocellular-dorsal stream mediates the function of the attention network. difficulties in spatial and temporal attention shifting impair letter-to-speech sound integration increasing neural noise. action video games improve the efficiency of the magnocellular-dorsal stream. the aim of this cutting-edge, round trip translation study is threefold: 1.to unravel new insights behind the pathophysiology of developmental dyslexia, 2. to assess gene-environment interaction effects on developmental dyslexia endophenotypes, and 3. to identify useful clues to foster the identification of new, personalized treatments.


Eligibility criteria:
inclusion criteria * 5-years old pre-readers, * normal intelligence quotient, * no main counter indications for magnetic resonance acquisition, * no previous diagnosis of any neurodevelopmental disorders. exclusion criteria: * intelligence quotient below the average range, * presence of counter indications for magnetic resonance acquisition, * previous diagnosis of any neurodevelopmental disorders.
promoting antiretroviral therapy among serodiscordant couples to reduce hiv transmission

Conditions: HIV

Summary: the purpose of this study is to evaluate the effectiveness of reducing hiv transmission among sero-discordant couples by applying comprehensive intervention components.

a cluster-randomized controlled trial was carried out in forty counties from 16 cities. the strategy of social marketing was applied to influence sero-discordant couples' behavioral changes including safer sexual intercourses, regular hiv testing for the negative partners, antiretroviral therapy initiation.

Eligibility criteria:
inclusion criteria: * couples are required to have a stable relationship and live together in the last 3 months; * older than 18 years and younger than 60 years; without regard to cd4 count; * open cohort(any newly diagnosed serodiscordant couples who are eligible for treatment will be included during the study period). exclusion criteria: * couples are not have a stable relationship or do not live together in the last 3 months; * younger than 18 years old.

Keywords: hiv serodiscordant couples hiv sero-conversion anti-retroviral therapy intervention